Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Sci Rep ; 12(1): 1237, 2022 01 24.
Article in English | MEDLINE | ID: mdl-35075208

ABSTRACT

The ability of MALDI-TOF for the identification of nontuberculous mycobacteria (NTM) has improved recently thanks to updated databases and optimized protein extraction procedures. Few multicentre studies on the reproducibility of MALDI-TOF have been performed so far, none on mycobacteria. The aim of this study was to evaluate the reproducibility of MALDI-TOF for the identification of NTM in 15 laboratories in 9 European countries. A total of 98 NTM clinical isolates were grown on Löwenstein-Jensen. Biomass was collected in tubes with water and ethanol, anonymized and sent out to the 15 participating laboratories. Isolates were identified using MALDI Biotyper (Bruker Daltonics). Up to 1330 MALDI-TOF identifications were collected in the study. A score ≥ 1.6 was obtained for 100% of isolates in 5 laboratories (68.2-98.6% in the other). Species-level identification provided by MALDI-TOF was 100% correct in 8 centres and 100% correct to complex-level in 12 laboratories. In most cases, the misidentifications obtained were associated with closely related species. The variability observed for a few isolates could be due to variations in the protein extraction procedure or to MALDI-TOF system status in each centre. In conclusion, MALDI-TOF showed to be a highly reproducible method and suitable for its implementation for NTM identification.


Subject(s)
Nontuberculous Mycobacteria/isolation & purification , Humans , Nontuberculous Mycobacteria/classification , Reproducibility of Results , Species Specificity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
2.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 36(2): 104-111, feb. 2018. tab
Article in Spanish | IBECS | ID: ibc-170699

ABSTRACT

El cultivo de micobacterias es la prueba de referencia, y la más sensible, en el diagnóstico microbiológico de la tuberculosis y de las infecciones por micobacterias no tuberculosas. Sin embargo, requiere al menos 2-3 semanas para ser positivo. La tinción, rápida, aunque poco sensible, actúa como un complemento. Las pruebas de amplificación genética tienen una sensibilidad intermedia y obtienen resultados en 1-2 días. Estas últimas están indicadas cuando el grado de sospecha es moderado o alto. En pacientes infectados por el VIH con inmunodepresión severa (<200 CD4) puede ser útil la detección de antígeno lipoarabinomanano en orina. La identificación de los aislamientos de los cultivos positivos es imprescindible para evaluar la significación clínica y la orientación terapéutica. Actualmente se dispone de un abanico de técnicas de identificación que facilitan resultados en periodos de solo 1-4 días. El futuro del diagnóstico pasa por un mayor desarrollo de las técnicas de amplificación genética y por potenciar la búsqueda de biomarcadores que permitan un nuevo enfoque del diagnóstico de estas infecciones (AU)


Mycobacterial culture has a high sensitivity and is the test of choice for the microbiological diagnosis of tuberculosis and nontuberculous mycobacterial infections. However, the results of this culture require at least 2-3 weeks to obtain positivity. Staining is rapid and can be used as a complementary study, although its sensitivity is low. Gene amplification tests have an intermediate sensitivity and obtain results in 1-2 days. These last tests are indicated in cases with moderate or high clinical suspicion. In HIV patients with severe immunodeficiency (<200 CD4), lipoarabinomannan antigen detection in urine may be useful. The identification of isolates from positive cultures is essential to evaluate the clinical significance of the culture results and consider the therapeutic options available. At present, there is a wide range of identification techniques available, which provide results within just 1-4 days. The future of diagnostic techniques in tuberculosis and nontuberculous mycobacterial infections lies in greater development of gene amplification techniques and promoting the search for biomarkers which enable a new approach to the diagnosis of these infections (AU)


Subject(s)
Humans , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium/isolation & purification , Tuberculosis/microbiology , Mycobacterium , Tuberculosis/diagnosis , Mycobacterium tuberculosis/isolation & purification , Algorithms , Staining and Labeling , Diagnosis, Differential , Chromatography, Affinity/methods , Gas Chromatography-Mass Spectrometry , High-Throughput Nucleotide Sequencing/methods
3.
Enferm Infecc Microbiol Clin (Engl Ed) ; 36(2): 104-111, 2018 Feb.
Article in English, Spanish | MEDLINE | ID: mdl-29287920

ABSTRACT

Mycobacterial culture has a high sensitivity and is the test of choice for the microbiological diagnosis of tuberculosis and nontuberculous mycobacterial infections. However, the results of this culture require at least 2-3 weeks to obtain positivity. Staining is rapid and can be used as a complementary study, although its sensitivity is low. Gene amplification tests have an intermediate sensitivity and obtain results in 1-2 days. These last tests are indicated in cases with moderate or high clinical suspicion. In HIV patients with severe immunodeficiency (<200 CD4), lipoarabinomannan antigen detection in urine may be useful. The identification of isolates from positive cultures is essential to evaluate the clinical significance of the culture results and consider the therapeutic options available. At present, there is a wide range of identification techniques available, which provide results within just 1-4 days. The future of diagnostic techniques in tuberculosis and nontuberculous mycobacterial infections lies in greater development of gene amplification techniques and promoting the search for biomarkers which enable a new approach to the diagnosis of these infections.


Subject(s)
Bacteriological Techniques , Mycobacterium Infections/diagnosis , Culture Media , DNA, Bacterial/genetics , Forecasting , HIV Infections/complications , Humans , Lipopolysaccharides/urine , Mycobacterium/growth & development , Mycobacterium/isolation & purification , Mycobacterium Infections/microbiology , Mycobacterium Infections/urine , Real-Time Polymerase Chain Reaction , Sequence Analysis, DNA , Specimen Handling , Staining and Labeling/methods , Time Factors
4.
Med. clín (Ed. impr.) ; 149(9): 399-405, nov. 2017. tab, mapas
Article in Spanish | IBECS | ID: ibc-168054

ABSTRACT

La aparición de la técnica Xpert(R) MTB/RIF supuso una revolución en el diagnóstico de la tuberculosis, especialmente en zonas con alta incidencia y pocos recursos. Permite la detección de Mycobacterium tuberculosis complex y, simultáneamente, de las mutaciones más comunes de resistencia a rifampicina en menos de 2 h. Su sensibilidad en muestras respiratorias es muy alta, pero disminuye en muestras extrapulmonares y en niños. Aunque más rápida y simple que los métodos convencionales, presenta ciertas limitaciones y aún son necesarias nuevas y mejores herramientas diagnósticas que contribuyan a reducir los casos y las muertes por tuberculosis. Esta revisión pretende compendiar la evidencia científica en torno al rendimiento diagnóstico de Xpert(R) MTB/RIF en diferentes tipos de muestras y poblaciones, así como analizar sus ventajas y limitaciones para el diagnóstico de tuberculosis (AU)


The advent of the Xpert(R) MTB/RIF technique was a revolution in the diagnosis of tuberculosis, especially in areas with high incidence and low resources. It allows the detection of Mycobacterium tuberculosis complex and simultaneously the most common resistance mutations to rifampicin in less than 2h. For respiratory samples the sensitivity is very high, but it decreases for extrapulmonary samples and children. Although it is faster and simpler than conventional methods, it presents some limitations and new and better techniques are needed to reduce the number of cases and deaths caused by tuberculosis. This review aims to assess the scientific evidence around the diagnostic performance of Xpert(R) MTB/RIF in different types of samples and populations, as well as analyse its strengths and limitations for TB diagnosis (AU)


Subject(s)
Humans , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Rifampin/therapeutic use , Drug Resistance , Coinfection/drug therapy , Sensitivity and Specificity , Mycobacterium tuberculosis , Mycobacterium tuberculosis/isolation & purification
5.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 35(8): 529-535, oct. 2017. tab
Article in Spanish | IBECS | ID: ibc-167842

ABSTRACT

Las micobacterias son un amplio grupo de microorganismos en el que múltiples especies son causa de una importante morbimortalidad, como la tuberculosis y la lepra. La aparición y diseminación de cepas del complejo Mycobacterium tuberculosis resistentes a diversos fármacos constituye en la actualidad uno de los problemas sanitarios de mayor gravedad a nivel mundial. Por otro lado, las micobacterias diferentes de M. tuberculosis y Mycobacterium leprae, denominadas micobacterias no tuberculosas (MNT), son aislamientos cada vez más frecuentes, requiriendo en muchos casos un tratamiento que precisa una orientación sobre la sensibilidad de estos microorganismos a los antimicrobianos. En el presente artículo se revisan los métodos para determinar la sensibilidad in vitro a los antimicobacterianos de los aislamientos del complejo M. tuberculosis y las MNT más relevantes. Además, también se realiza un análisis de las técnicas moleculares de detección rápida de la resistencia a partir de las muestras clínicas (AU)


Mycobacteria are a large group of microorganisms, multiple species of which are major causes of morbidity and mortality, such as tuberculosis and leprosy. At present, the emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis complex are one of the most serious health problems worldwide. Furthermore, in contrast to M. tuberculosis and Mycobacterium leprae, non-tuberculous mycobacteria (NTM) are more frequently isolated and, in many cases, treatment is based on drug susceptibility testing. This article is a review of the different methods to determine the in vitro drug susceptibility of M. tuberculosis complex and the most relevant NTM isolates. The molecular techniques currently used for rapid detection of resistance of clinical specimens are also analysed (AU)


Subject(s)
Anti-Infective Agents/therapeutic use , Mycobacterium/isolation & purification , Mycobacterium Infections/microbiology , Drug Resistance , Drug Resistance, Microbial , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/trends , Nontuberculous Mycobacteria , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/microbiology
6.
Med Clin (Barc) ; 149(9): 399-405, 2017 Nov 09.
Article in English, Spanish | MEDLINE | ID: mdl-28739268

ABSTRACT

The advent of the Xpert® MTB/RIF technique was a revolution in the diagnosis of tuberculosis, especially in areas with high incidence and low resources. It allows the detection of Mycobacterium tuberculosis complex and simultaneously the most common resistance mutations to rifampicin in less than 2h. For respiratory samples the sensitivity is very high, but it decreases for extrapulmonary samples and children. Although it is faster and simpler than conventional methods, it presents some limitations and new and better techniques are needed to reduce the number of cases and deaths caused by tuberculosis. This review aims to assess the scientific evidence around the diagnostic performance of Xpert® MTB/RIF in different types of samples and populations, as well as analyse its strengths and limitations for TB diagnosis.


Subject(s)
Mycobacterium tuberculosis/drug effects , Nucleic Acid Amplification Techniques , Rifampin/pharmacology , Tuberculosis/diagnosis , Bacterial Proteins/genetics , Comorbidity , DNA, Bacterial/genetics , DNA-Directed RNA Polymerases/genetics , Drug Resistance, Bacterial/genetics , Female , HIV Infections/epidemiology , Humans , Incidence , Male , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Rifampin/therapeutic use , Sensitivity and Specificity , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Tuberculosis/microbiology , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Multidrug-Resistant/microbiology
7.
Enferm Infecc Microbiol Clin ; 35(8): 529-535, 2017 Oct.
Article in English, Spanish | MEDLINE | ID: mdl-27236235

ABSTRACT

Mycobacteria are a large group of microorganisms, multiple species of which are major causes of morbidity and mortality, such as tuberculosis and leprosy. At present, the emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis complex are one of the most serious health problems worldwide. Furthermore, in contrast to M. tuberculosis and Mycobacterium leprae, non-tuberculous mycobacteria (NTM) are more frequently isolated and, in many cases, treatment is based on drug susceptibility testing. This article is a review of the different methods to determine the in vitro drug susceptibility of M. tuberculosis complex and the most relevant NTM isolates. The molecular techniques currently used for rapid detection of resistance of clinical specimens are also analysed.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Microbial Sensitivity Tests/methods , Mycobacterium/drug effects , Antitubercular Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Humans , Molecular Diagnostic Techniques , Mycobacterium/classification , Mycobacterium Infections/microbiology , Nontuberculous Mycobacteria/drug effects , Species Specificity
14.
J Antimicrob Chemother ; 66(10): 2277-80, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21791442

ABSTRACT

OBJECTIVES: We analysed the ability of Mycobacterium tuberculosis clinical isolates to penetrate and grow inside murine macrophages as a surrogate of fitness. METHODS: Thirty-five drug-resistant and 10 drug-susceptible M. tuberculosis isolates were studied in a murine macrophage model from the J774.2 cell line in a 6 day protocol, performing semi-quantitative counts in Middlebrook 7H11 medium. The mycobacterial penetration index (MPI) after infection and the mycobacterial growth ratio (MGR) inside the macrophages were determined to evaluate the fitness of isolates. RESULTS: Isolates with the katG S315T mutation and multidrug-resistant (MDR) isolates had a significantly lower MGR compared with drug-susceptible isolates. The MPI of the isolates with the katG S315T mutation showed a significant decrease compared with the MPI of those without this mutation. A trend to significantly lower values was also observed on comparing the MPI of the MDR isolates with that of the drug-susceptible isolates and the isolates resistant to isoniazid. CONCLUSIONS: The isoniazid-resistant and MDR isolates with mutations in the katG gene showed decreased multiplication inside murine macrophages, suggesting a lower fitness of M. tuberculosis with these resistance patterns.


Subject(s)
Antitubercular Agents/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Macrophages/microbiology , Mycobacterium tuberculosis/growth & development , Animals , Bacterial Proteins/genetics , Catalase/genetics , Cell Line , DNA-Directed RNA Polymerases , Humans , Isoniazid/pharmacology , Mice , Microbial Sensitivity Tests , Mutation , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Oxidoreductases/genetics
16.
Infect Genet Evol ; 11(1): 132-8, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20920607

ABSTRACT

IS6110, a Mycobacterium tuberculosis complex species-specific insertion element, is targeted primarily for DNA fingerprinting of M. tuberculosis strains. The number and chromosomal positions of copies of this element have been found to be highly variable between unrelated strains and have been exploited for molecular epidemiological purpose but the utility of IS6110 as an informative marker of strain phylogeny has yet to be demonstrated. In the current study, a recently proposed IS6110-targetting PCR based typing methodology, fluorescent amplified fragment length polymorphism (fAFLP) was applied to a global panel of 166 of the clinically more predominant 'modern' strains characterised by spoligotype and, where available, Variable Number Tandem Repeat (VNTR) to identify potentially evolutionarily informative common fragments that could define strains as belonging to established genetic lineages. These common fragments are hereby proposed to be ancestral insertion sites present in common ancestors of these strains rather than preferential insertion sites or 'hot spots'. Results indicate that the exact same spoligotype and VNTR-defined lineages are reflected in the fragment patterns but with greater resolution and are able to clearly define the very distinct Haarlem, LAM, X and also the currently ill-defined T and S and lineages and spoligotypes designated as U, or unknown, without ambiguity. The biogeographical patterns generated reflect the migration of mankind across the globe and indicate that only four successful clones (or individual bacteria) gave rise to virtually all of the tuberculosis in Europe and the Americas. Potential lies in the application of the data to determine IS6110 evolutionary events that have occurred during the evolution of these lineages.


Subject(s)
Mycobacterium tuberculosis/classification , Phylogeny , Minisatellite Repeats , Molecular Epidemiology , Mycobacterium tuberculosis/genetics , Polymerase Chain Reaction , Sequence Alignment
18.
J Antimicrob Chemother ; 65(11): 2341-6, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20802233

ABSTRACT

OBJECTIVES: To determine the proportion and type of mutations in Mycobacterium tuberculosis isolates resistant to streptomycin, and their relationship with the level of resistance and with the epidemiological molecular pattern of the isolates. METHODS: Sixty-nine streptomycin-resistant isolates from a M. tuberculosis strain collection (1995-2005) from Barcelona were studied. The MIC of streptomycin for each isolate was determined using the proportions method with Middlebrook 7H11 medium. The entire rpsL gene and two specific fragments of the rrs gene (the 530 loop and the 912 region) were sequenced. IS6110-restriction fragment length polymorphism and spoligotyping were performed in each isolate. RESULTS: Twenty-six (26/69, 37.7%) streptomycin-resistant isolates presented a mutation in either the rpsL gene and/or the rrs530 loop, with no mutation in the rrs912 region. Seventeen (24.6%) isolates showed rpsL mutations (codons 43 and 88) associated with high MIC levels. Nine (13.0%) isolates had alterations in the rrs gene (A513T, A513C and C516T). Nineteen isolates (19/64, 29.7%) were classified into seven clusters (containing 2-5 isolates per cluster). Nineteen different spoligotype patterns were found. All the LAM3 spoligotype isolates (10/67, 14.9%) were associated with a C491T change in the rrs gene, being also observed in all LAM3 streptomycin-susceptible isolates. CONCLUSIONS: Mutations in the rpsL and rrs genes were detected in 37.7% of streptomycin-resistant M. tuberculosis isolates. High-level resistance was associated with mutations in the rpsL gene, whereas wild-type isolates showed low MIC levels. The presence of the C491T substitution in the rrs gene in streptomycin-susceptible and -resistant isolates demonstrates that this change is an epidemiological marker associated with LAM3 sublineage.


Subject(s)
Antitubercular Agents/pharmacology , Drug Resistance, Bacterial , Mutation, Missense , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Streptomycin/pharmacology , Tuberculosis/microbiology , Bacterial Typing Techniques , DNA Fingerprinting , DNA Transposable Elements , DNA, Bacterial/genetics , Humans , Microbial Sensitivity Tests , Mycobacterium tuberculosis/isolation & purification , Ribosomal Proteins/genetics , Spain
19.
Arch Bronconeumol ; 46(5): 255-74, 2010 May.
Article in Spanish | MEDLINE | ID: mdl-20444533

ABSTRACT

Pulmonary TB should be suspected in patients with respiratory symptoms longer than 2-3 weeks. Immunosuppression may modify clinical and radiological presentation. Chest X-ray shows very suggestive, albeit sometimes atypical, signs of TB. Complex radiological tests (CT scan, MR) are more useful in extrapulmonary TB. At least 3 serial representative samples of the clinical location are used for diagnosis whenever possible. Bacilloscopy and liquid medium cultures are indicated in all cases. Genetic amplification techniques are coadjuvant in moderate or high TB suspicion. Administration of isoniazid, rifampicin, ethambutol and pyrazinamide (HREZ) for 2 months and HR for 4 additional months is recommended in new cases of TB, except in cases of meningitis in which treatment should continue for up to 12 months and up to 9 months in spinal TB with neurological involvement, and in silicosis. Appropriate adjustments with antiretroviral treatment should be made in HIV patients. Combined therapy is recommended to avoid development of resistance. An antibiogram to first line drugs should be performed in all the initial isolations of new patients. Treatment control is one of the most important activities in TB management. The Tuberculin Skin Test (TST) is positive in TB infection when >or=5mm, and Interferon-Gamma Release Assays (IGRA) are recommended in combination with TT. The standard treatment schedule for infection is 6 months with isoniazid. In pulmonary TB, respiratory isolation is applied for 3 weeks or until 3 negative bacilloscopy samples are obtained.


Subject(s)
Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/drug therapy , Algorithms , Humans , Practice Guidelines as Topic , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/microbiology , Tuberculosis, Pulmonary/prevention & control
20.
Enferm Infecc Microbiol Clin ; 28(5): 297.e1-20, 2010 May.
Article in Spanish | MEDLINE | ID: mdl-20435388

ABSTRACT

Pulmonary TB should be suspected in patients with respiratory symptoms longer than 2-3 weeks. Immunosuppression may modify clinical and radiological presentation. Chest x-ray shows very suggestive, albeit sometimes atypical, signs of TB. Complex radiological tests (CT scan, MR) are more useful in extrapulmonary TB. At least 3 serial representative samples of the clinical location are used for diagnosis whenever possible. Bacilloscopy and liquid medium cultures are indicated in all cases. Genetic amplification techniques are coadjuvant in moderate or high TB suspicion. Administration of isoniazid, rifampicin, ethambutol and pyrazinamide (HREZ) for 2 months and HR for 4 additional months is recommended in new cases of TB, except in cases of meningitis in which treatment should continue for up to 12 months and up to 9 months in spinal TB with neurological involvement, and in silicosis. Appropriate adjustments with antiretroviral treatment should be made in HIV patients. Combined therapy is recommended to avoid development of resistance. An antibiogram to first line drugs should be performed in all the initial isolations of new patients. Treatment control is one of the most important activities in TB management. The Tuberculin Skin Test (TST) is positive in TB infection when >or=5mm, and Interferon-Gamma Release Assays (IGRA) are recommended in combination with TT. The standard treatment schedule for infection is 6 months with isoniazid. In pulmonary TB, respiratory isolation is applied for 3 weeks or until 3 negative bacilloscopy samples are obtained.


Subject(s)
Tuberculosis/diagnosis , Tuberculosis/therapy , Algorithms , Humans , Practice Guidelines as Topic , Tuberculosis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...